相关临床试验
41
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
8
19.5%
已完成
13
31.7%
尚未招募
1
2.4%
招募中
19
46.3%
暂无批准数据
- The Commercial Court of Lyon has approved Poxel's recovery plan and ended the judicial reorganization proceedings that began on August 5, 2025. - The recovery plan includes establishing new partnerships for Imeglimin commercialization in Asia, promoting PXL770 for ADPKD, and leveraging PXL065 for HCM. - Financial restructuring involves €5 million equity line from IRIS, €3.75 million bond borrowings from IPF, and capital increases to strengthen the company's position. - The plan enables Poxel to continue developing its metabolic disease portfolio while settling outstanding liabilities and optimizing cost structure.
- Oncodesign Precision Medicine has submitted its REVERT Phase 1b/2a clinical trial protocol for OPM-101 to Swiss regulatory authorities, targeting advanced melanoma patients resistant to anti-PD1 therapy. - The company reported a net income of €9.8 million for the first half of 2025, primarily due to the €13 million valuation of reintegrated OPM-201 inventory from its partnership with Servier. - Despite implementing significant cost reduction measures including employee layoffs and executive pay cuts, OPM faces funding challenges with only €2.5 million in cash reserves as of June 30, 2025. - The company is actively seeking partnerships or asset transfers for its two lead kinase inhibitors, OPM-101 and OPM-201, while establishing a €5 million equity financing line to address market uncertainties.
- Topcon Healthcare acquired Intelligent Retinal Imaging Systems (IRIS), a cloud-based retinal screening technology company, to integrate AI-powered diabetic retinopathy screening into its Healthcare from the Eye initiative. - IRIS has enabled over 1.8 million screenings and identified more than 279,000 cases of diabetic retinopathy across 650+ healthcare organizations since its founding in 2012. - The acquisition will strengthen Topcon's Harmony platform by adding IRIS's referral and communication capabilities to improve care coordination between primary care and eye care providers. - The integration aims to enable early identification of patients at risk of ocular disease during primary care visits and facilitate timely referrals to eye care specialists.
